A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Mirati Therapeutics Inc.
Summary
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Cohort A\* (closed): Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (squamous or nonsquamous) KRASG12C mutation and histologically confirmed PD-L1 TPS ≥1%. * Cohort C: Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (non-squamous only) KRASG12C mutation and histologically confirmed PD-L1 TPS \< 50% AND previously completed 4 cycles of standard-of-care platinum based induction chemotherapy with pembrolizumab AND experienced stable disease, partial response, or complete response per investigator's assessment after 4 cycles…
Interventions
- DrugAdagrasib oral dose of 400 mg twice daily tablets
oral dose of 400 mg twice daily tablets
- Combination ProductPembrolizumab
IV infusion once every 3 weeks
- Combination ProductChemotherapy: Pemetrexed
IV infusion once every 3 weeks
- Combination ProductCisplatin/Carboplatin
IV infusion once every 3 weeks
Locations (166)
- Local Institution - Unk025Anchorage, Alaska
- Local Institution - 017-591Glendale, Arizona
- Local Institution - 017-821Phoenix, Arizona
- Local Institution - Unk047Anaheim, California
- Local Institution - 017-936CFountain Valley, California
- MemorialCare - Orange Coast Medical CenterFountain Valley, California